Has Acutaas Chemical declared dividend?

Acutaas Chemicals Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of September 18, 2023. Despite this, the dividend yield is 0%, as the company has not provided significant dividend returns in recent years, although it has shown strong price performance.

Acutaas Chemicals Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 18 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Acutaas Chemicals Ltd achieved a price return of 3.82%, with no dividend return, resulting in a total return of 3.82%.<BR><BR>Over the past year, the company saw a price return of 89.48%, with no dividend return, leading to a total return of 89.48%.<BR><BR>In the 2-year period, the price return was 91.7%, with a dividend return of 0.46%, culminating in a total return of 92.16%.<BR><BR>For the 3-year period, the price return reached 146.75%, with a dividend return of 1.41%, resulting in a total return of 148.16%.<BR><BR>In the last 4 years, there was no price or dividend return, resulting in a total return of 0.0%.<BR><BR>Over the 5-year period, the company also recorded no price or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, Acutaas Chemicals Ltd has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price performance, particularly in the 1 and 3-year periods, despite the lack of significant dividend contributions.

Is Acutaas Chemical overvalued or undervalued?

As of September 17, 2021, Acutaas Chemical is considered very expensive and overvalued with a PE ratio of 58.75, significantly higher than its peers, despite strong returns of 84.28% over the past year, which outperformed the Sensex's 7.55% return.

As of 17 September 2021, Acutaas Chemical's valuation grade has moved from does not qualify to very expensive, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key financial ratios include a PE ratio of 58.75, an EV to EBITDA ratio of 39.16, and a PEG ratio of 0.64, which suggest that despite a high growth potential, the current price does not justify the earnings.<BR><BR>In comparison to its peers, Acutaas Chemical's PE ratio is notably higher than Godrej Industries Ltd., which has a PE of 46.63, and Deepak Nitrite Ltd., with a PE of 37.97. This reinforces the notion that Acutaas is trading at a premium relative to companies within the same sector. Additionally, while Acutaas has shown strong returns over the past year at 84.28%, it has underperformed against the Sensex's return of 7.55% during the same period, further highlighting its overvaluation in the current market context.

Who are the peers of the Acutaas Chemical?

Acutaas Chemical's peers include Alivus Life, Sanofi Consumer, Granules India, Marksans Pharma, P & G Health Ltd, Akums Drugs, Shilpa Medicare, Aarti Pharma, Strides Pharma, and FDC. Acutaas Chemical has an average management risk, good growth, and an 80.40% one-year return, while Strides Pharma leads with a 104.24% return.

Peers: The peers of Acutaas Chemical are Alivus Life, Sanofi Consumer, Granules India, Marksans Pharma, P & G Health Ltd, Akums Drugs, Shilpa Medicare, Aarti Pharma, Strides Pharma, and FDC.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd, while Good management risk is found at Alivus Life, Granules India, Marksans Pharma, and the rest. Average management risk is noted for Acutaas Chemical, Akums Drugs, Shilpa Medicare, Aarti Pharma, and FDC, while Strides Pharma has Below Average management risk. Growth is rated as Good for Acutaas Chemical, while Below Average growth is seen in Alivus Life, Granules India, Marksans Pharma, P & G Health Ltd, Akums Drugs, Shilpa Medicare, and Aarti Pharma, with the rest not qualifying. Capital Structure is Excellent for Alivus Life, Granules India, Marksans Pharma, P & G Health Ltd, Acutaas Chemical, and Aarti Pharma, while Good is noted for Akums Drugs, and Below Average for Shilpa Medicare and Strides Pharma.<BR><BR>Return Snapshot: Acutaas Chemical has a 1-year return of 80.40%, while Strides Pharma has the highest return at 104.24%, and Granules India has the lowest at -3.35%. Acutaas Chemical's return is lower than Strides Pharma's but significantly higher than Granules India's. Additionally, Granules India and Akums Drugs have negative six-month returns.

Who are in the management team of Acutaas Chemical?

As of March 2023, the management team of Acutaas Chemical includes Nareshbhai Ramjibhai Patel (Chairman/Executive Director), Chetankumar Chhaganlal Vaghasia, Virendra Nath Mishra, and Ram Mohan Rao Locande (all Whole-time Directors), along with four Independent Non-Executive Directors: Girikrishna Maniar, Hetal Gandhi, Richa M. Goyal, and Anita Bandyopadhyay.

As of March 2023, the management team of Acutaas Chemical includes the following members:<BR><BR>1. Nareshbhai Ramjibhai Patel - Chairman / Executive Director<BR>2. Chetankumar Chhaganlal Vaghasia - Whole-time Director<BR>3. Virendra Nath Mishra - Whole-time Director<BR>4. Ram Mohan Rao Locande - Whole-time Director<BR>5. Girikrishna Maniar - Independent Non-Executive Director<BR>6. Hetal Gandhi - Independent Non-Executive Director<BR>7. Richa M. Goyal - Independent Non-Executive Director<BR>8. Anita Bandyopadhyay - Independent Non-Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

What does Acutaas Chemical do?

Acutaas Chemicals Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹3,085 Cr and a net profit of ₹625 Cr for the quarter ending March 2025. It was originally established as "Ami Organics" in 2004 and later incorporated as a private limited company in 2007.

Overview:<BR>Acutaas Chemicals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was initially formed as a partnership firm named "Ami Organics" on 03 January, 2004, in Surat, India. It converted into a Private Limited Company under the name "Ami Organics Private Limited" with a Certificate of Incorporation dated 12 June, 2007. The latest quarterly results report net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3,085 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 625 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 9,700 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 63.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.18<BR>- Return on Equity: 12.12%<BR>- Price to Book: 7.43<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Who are the top shareholders of the Acutaas Chemical?

The top shareholders of Acutaas Chemical include promoters, with Nareshkumar Ramjibhai Patel holding 19.34%, institutional investors with 19 mutual funds owning 13.02% and 110 foreign institutional investors holding 16.48%, and individual investors collectively owning 24.19%. The SBI Large & Midcap Fund is the largest public shareholder at 4.23%.

The top shareholders of Acutaas Chemical include a mix of promoters, institutional investors, and individual shareholders. The majority of the shares are held by promoters, with Nareshkumar Ramjibhai Patel being the promoter with the highest holding at 19.34%. <BR><BR>In terms of institutional investment, 19 mutual funds collectively hold 13.02% of the shares, while 110 foreign institutional investors (FIIs) hold 16.48%. The highest public shareholder is the SBI Large & Midcap Fund, which holds 4.23%. Additionally, individual investors collectively own 24.19% of the company.

How big is Acutaas Chemical?

As of 24th July, Acutaas Chemicals Ltd has a market capitalization of 9,723.00 Cr, with net sales of 1,006.87 Cr and a net profit of 158.71 Cr in the latest four quarters. The company reported shareholder's funds of 674.00 Cr and total assets of 1,095.90 Cr for the annual period ending March 2024.

As of 24th July, Acutaas Chemicals Ltd has a market capitalization of 9,723.00 Cr and is classified as a Mid Cap company.<BR><BR>In the latest four quarters, Acutaas Chemicals reported net sales of 1,006.87 Cr and a net profit of 158.71 Cr.<BR><BR>For the latest annual period ending March 2024, the company had shareholder's funds of 674.00 Cr and total assets amounting to 1,095.90 Cr.

When is the next results date for Acutaas Chemical?

The next results date for Acutaas Chemical is July 30, 2025.

The next results date for Acutaas Chemical is scheduled for July 30, 2025.

Is Acutaas Chemical technically bullish or bearish?

As of October 1, 2025, the technical trend has shifted to bullish with strong indicators like the weekly MACD and Bollinger Bands supporting upward momentum, although caution is advised due to a mildly bearish monthly MACD and Dow Theory on the weekly timeframe.

As of 1 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating upward momentum. Daily moving averages are also bullish, reinforcing the positive trend. However, the monthly MACD is mildly bearish and the Dow Theory shows a mildly bearish stance on the weekly timeframe, which suggests some caution. Overall, the strength of the bullish trend is supported by the KST being bullish on both weekly and monthly timeframes.

Are Acutaas Chemical latest results good or bad?

Acutaas Chemicals' latest results are very good, with a 24.10% revenue increase to ₹306.20 crores and a 93.47% rise in net profit to ₹72.24 crores year-on-year, alongside strong stock performance. This reflects robust demand and effective cost management, positioning the company favorably in the market.

Acutaas Chemicals' latest results are quite impressive, reflecting strong operational performance. In the September quarter, the company reported a revenue increase of 24.10% year-on-year, reaching ₹306.20 crores, and a remarkable net profit of ₹72.24 crores, which is up 93.47% year-on-year. The operating profit margins also expanded significantly to 31.13%, an increase of 1,130 basis points compared to the previous year.<BR><BR>The stock has shown strong momentum, gaining 12.46% over the past week and 36.26% over the last three months, outperforming both the Sensex and the broader chemicals sector. This performance indicates robust demand and effective cost management, positioning Acutaas Chemicals favorably in the market.<BR><BR>Overall, the results can be characterized as very good, showcasing the company's ability to capitalize on favorable market conditions while maintaining strong financial health.

How has been the historical performance of Acutaas Chemical?

Acutaas Chemical has shown significant growth over the past five years, with net sales increasing from 340.61 Cr in March 2021 to 1,006.88 Cr in March 2025, and profit after tax rising from 54.00 Cr to 160.42 Cr in the same period. The company's total assets also expanded from 231.89 Cr to 1,549.26 Cr, reflecting strong operational efficiency and profitability.

Answer:<BR>The historical performance of Acutaas Chemical shows significant growth in net sales and profitability over the past five years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Acutaas Chemical's net sales have increased from 340.61 Cr in March 2021 to 1,006.88 Cr in March 2025, reflecting a strong upward trend. The total operating income has similarly risen, reaching 1,006.88 Cr in March 2025, up from 340.61 Cr in March 2021. The company's operating profit (PBDIT) has also shown substantial growth, climbing from 81.54 Cr in March 2021 to 249.01 Cr in March 2025, indicating improved operational efficiency. Profit before tax surged to 216.16 Cr in March 2025 from 71.73 Cr in March 2021, while profit after tax reached 160.42 Cr, up from 54.00 Cr in March 2021. The consolidated net profit for March 2025 stood at 158.71 Cr, a significant increase from 42.77 Cr in March 2024. Furthermore, total assets have expanded from 231.89 Cr in March 2020 to 1,549.26 Cr in March 2025, with total liabilities increasing from 231.89 Cr to 1,549.26 Cr in the same period. The cash flow from operating activities has remained positive, amounting to 118.00 Cr in March 2025, although cash flow from investing activities has been negative at -223.00 Cr. Overall, Acutaas Chemical has demonstrated robust growth in revenue and profitability, alongside a significant increase in total assets and liabilities.

Should I buy, sell or hold Acutaas Chemical?

Which are the latest news on Acutaas Chemical?

Why is Acutaas Chemical falling/rising?

As of 04-Dec, Acutaas Chemicals Ltd's stock price is at 1,708.80, down -1.35% and has underperformed significantly over the past week and month compared to the Sensex. Despite strong long-term growth, recent trends show declining investor interest and negative market sentiment.

As of 04-Dec, Acutaas Chemicals Ltd's stock price is falling, currently at 1,708.80, reflecting a change of -23.45 (-1.35%). The stock has been underperforming, having lost -6.98% over the last four consecutive days. This decline is further highlighted by its performance today, where it underperformed its sector by -1.14%. <BR><BR>In the past week, the stock has decreased by -4.41%, while the benchmark Sensex has only fallen by -0.53%. Over the past month, Acutaas Chemicals has seen a more significant drop of -6.68%, contrasting with the Sensex's gain of +2.16%. Although the stock has shown impressive long-term growth, with a year-to-date increase of +58.92% and a one-year return of +49.57%, the recent trend indicates a downturn.<BR><BR>Investor participation has also declined, with delivery volume on December 3 falling by -33.25% compared to the five-day average, suggesting reduced interest from investors. Despite the company's strong fundamentals, such as a low debt-to-equity ratio and healthy growth in net sales and profits, the current market sentiment appears to be negative, contributing to the stock's recent price decline.